BioSpace News Archive

Boston Therapeutics, Inc. today announced that it has entered into a securities purchase agreement with accredited investors (the “Investors”) pursuant to which the Company issued senior secured convertible notes (the “Notes”) in an aggregate principal amount of approximately $8.4 million for an aggregate purchase price of approximately $7.9 million.

Data from the SURPASS global clinical development program for Eli Lilly and Company’s tirzepatide, a novel investigational once-weekly medication for the treatment of type 2 diabetes, demonstrates statistically significant A1C and weight reductions versus several comparators.

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2021 on Tuesday, July 27, 2021 at 8:00 a.m. EDT .

Inova Diagnostics, a worldwide leader in IVD systems and reagents for autoimmune disease in the clinical laboratory, is pleased to announce FDA 510(k) clearance of its Aptiva® System and Aptiva® Celiac Disease IgA assay.

Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for CPI-613® (devimistat) for the treatment of biliary cancer.

RaySearch Laboratories AB announces that RayStation®* now is in clinical use at Mahatma Gandhi Cancer Hospital & Research Institute, in Visakhapatnam, India making this the first photon treatment using Raystation in the country.

The webinar is the first of many for Relay, the panelists came together to discuss key cybersecurity issues and the recent Executive Order on Improving Cybersecurity in the United States by the Biden Administration.

The market is estimated to grow with a CAGR of 8.1% from 2018-2025.

The market is estimated to grow with a CAGR of 5.5% from 2021 to 2028.

The market is estimated to grow with a CAGR of 8.1% from 2018-2025.